FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma

    NEXT STORY
    GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES
    PREV STORY
    Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Iterum Therapeutics plc Announces $10 Million Bought Deal Public Offering of Ordinary Shares

    author_avatar
    NASDAQ Market News

    Trinity Biotech plc to Announce Third Quarter 2020 Financial Results

    author_avatar
    NASDAQ Market News

    Curis to Release Fourth Quarter and Year End 2015 Financial Results and Hold Conference Call on February 29, 2016

    LEXINGTON, Mass., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company ...

    author_avatar
    NASDAQ Market News